Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.51 |
| ▸ | GIPR | P48546 | 3/20 | 0.45 |
| ▸ | GCG | P01275 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2663313 | 0.89 | GCGR (0.48) | GCGRGIPRGCG | |
| SCHEMBL9072812 | 0.86 | GCGR (0.49) | GCGRGIPRGCG | |
| SCHEMBL9072813 | 0.86 | GCGR (0.53) | GCGRGIPRGCG | |
| SCHEMBL2663311 | 0.85 | GCGR (0.49) | GCGRGIPRGCG | |
| SCHEMBL2663245 | 0.84 | GCGR (0.53) | GCGRGIPRGCG | |
| SCHEMBL2663254 | 0.81 | GCGR (0.54) | GCGRGIPR | |
| SCHEMBL4081395 | 0.81 | GCGR (0.53) | GCGRGIPR | |
| SCHEMBL4082060 | 0.80 | GCGR (0.53) | GCGRGIPRGCG | |
| SCHEMBL9072735 | 0.79 | GCGR (0.54) | GCGRGIPRGCG | |
| SCHEMBL9072733 | 0.79 | GCGR (0.46) | GCGRGIPRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GCG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.